- Home
- TFIN vs NTLA Comparison
TFIN vs NTLA Comparison
Compare TFIN & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TFIN
- NTLA
- Stock Information
- Founded
- TFIN 1981
- NTLA 2014
- Country
- TFIN United States
- NTLA United States
- Employees
- TFIN N/A
- NTLA N/A
- Industry
- TFIN Major Banks
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- TFIN Finance
- NTLA Health Care
- Exchange
- TFIN Nasdaq
- NTLA Nasdaq
- Market Cap
- TFIN 1.3B
- NTLA 1.2B
- IPO Year
- TFIN N/A
- NTLA 2016
- Fundamental
- Price
- TFIN $54.17
- NTLA $10.86
- Analyst Decision
- TFIN Hold
- NTLA Buy
- Analyst Count
- TFIN 4
- NTLA 20
- Target Price
- TFIN $70.75
- NTLA $32.30
- AVG Volume (30 Days)
- TFIN 264.1K
- NTLA 4.6M
- Earning Date
- TFIN 07-16-2025
- NTLA 08-07-2025
- Dividend Yield
- TFIN N/A
- NTLA N/A
- EPS Growth
- TFIN N/A
- NTLA N/A
- EPS
- TFIN 0.44
- NTLA N/A
- Revenue
- TFIN $409,227,000.00
- NTLA $52,857,000.00
- Revenue This Year
- TFIN $12.07
- NTLA N/A
- Revenue Next Year
- TFIN $14.74
- NTLA N/A
- P/E Ratio
- TFIN $116.65
- NTLA N/A
- Revenue Growth
- TFIN 2.49
- NTLA 14.99
- 52 Week Low
- TFIN $42.90
- NTLA $5.90
- 52 Week High
- TFIN $110.58
- NTLA $24.16
- Technical
- Relative Strength Index (RSI)
- TFIN 40.27
- NTLA 44.54
- Support Level
- TFIN $51.20
- NTLA $10.57
- Resistance Level
- TFIN $55.89
- NTLA $11.54
- Average True Range (ATR)
- TFIN 2.29
- NTLA 0.79
- MACD
- TFIN -0.82
- NTLA -0.32
- Stochastic Oscillator
- TFIN 20.87
- NTLA 7.73
About TFIN Triumph Financial Inc.
Triumph Financial Inc is a financial holding company. The company has four reportable segments namely Banking, Factoring, Payments, and Intelligence. The Banking segment includes the operations of TBK Bank. The Factoring segment includes the operations of Triumph Financial Services with revenue derived from factoring services, The Payments segment includes the operations of TBK Bank's TriumphPay division which provides a presentment, audit and payment solution to Shipper, Broker, and Factor clients in the trucking industry and The Intelligence segment includes to turn the over-the-road trucking data collected through the services into actionable insights for their customers.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.